<!DOCTYPE html>
<html lang="en">
  <head>
    <!-- Required meta tags -->
    <meta charset="utf-8" />
    <meta
      name="viewport"
      content="width=device-width, initial-scale=1, shrink-to-fit=no"
    />
    <link rel="icon" href="favicon.ico" />
    <!-- Bootstrap CSS -->
    <link
      rel="stylesheet"
      href="https://stackpath.bootstrapcdn.com/bootstrap/4.5.2/css/bootstrap.min.css"
      integrity="sha384-JcKb8q3iqJ61gNV9KGb8thSsNjpSL0n8PARn9HuZOnIxN0hoP+VmmDGMN5t9UJ0Z"
      crossorigin="anonymous"
    />
    <link rel="stylesheet" href="./style.css" />
    <script src="https://kit.fontawesome.com/5901743741.js"></script>
    <title>NeuroPn</title>
  </head>
  <body>
    <nav class="navbar navbar-expand-lg">
      <button class="brand-button">
        <!-- <a class="navbar-brand" href="index.html">NeuroPn</a> -->
        <a href="index.html"> <img src="./logo.png" /> </a>
      </button>
      <button
        class="navbar-toggler"
        data-toggle="collapse"
        data-target="#navbar-menu"
      >
        <i class="fas fa-bars menu"></i>
      </button>
      <div id="navbar-menu" class="collapse navbar-collapse">
        <ul class="navbar-nav ml-auto">
          <li class="nav-item">
            <a class="nav-link" href="index.html">Home</a>
          </li>
          <li class="nav-item">
            <a class="nav-link" href="team.html">Our Team</a>
          </li>
          <li class="nav-item">
            <a class="nav-link" href="science.html">Our Focus</a>
          </li>
          <li class="nav-item">
            <a class="nav-link" href="approach.html">Our Approach</a>
          </li>
          <li class="nav-item">
            <a class="nav-link" href="contact.html">Contact Us</a>
          </li>
        </ul>
      </div>
    </nav>

    <div class="content">
      <h2 class="heading">Our Focus</h2>
      <p>
        NeuroPn Therapeutics is focused on developing treatments that address
        underlying disease mechanism and deliver innovative therapies with
        superior efficacy and improved safety profile over the marketed drugs.
      </p>
      <div class="science-container">
        <h4 class="science-title">Parkinson's Disease</h4>
        <button
          class="btn learn-btn"
          type="button"
          data-toggle="collapse"
          data-target="#learn-more-one"
          aria-expanded="false"
          aria-controls="collapseExample"
        >
          Learn More
        </button>
        <div class="collapse" id="learn-more-one">
          <div class="card card-body">
            <p>
              Parkinsons’s disease (PD) is a chronic and progressive
              degenerative movement disorder that affects over 1.5 million
              Americans. Currently marketed dopamine replacement therapy can
              alleviate motor symptoms in PD, but there are no therapies that
              target the underlying neurodegenerative processes. Despite intense
              research, molecular mechanisms causing neuronal loss are not fully
              understood which has hampered the development of new drugs and
              disease modifying therapies.
            </p>
            <p>
              Neuroinflammation and mitochondrial dysfunction with associated
              oxidative/endoplasmic reticulum (ER) stress all work
              synergistically to accelerate Parkinson’s disease (PD)
              progression.
            </p>
            <div class="science-image no-top-margin">
              <img src="images/parkinson.png" />
            </div>
          </div>
        </div>
      </div>
      <div class="science-container">
        <h4 class="science-title">Oncology</h4>
        <button
          class="btn learn-btn"
          type="button"
          data-toggle="collapse"
          data-target="#learn-more-two"
          aria-expanded="false"
          aria-controls="collapseExample"
        >
          Learn More
        </button>
        <div class="collapse" id="learn-more-two">
          <div class="card card-body">
            <p>
              Despite emergence of innovative therapies, cancer remains among
              the leading causes of death globally. Chemotherapy remains a
              frontline treatment for many malignancies but accumulating
              evidence suggests that chemotherapy and radiation generated tumor
              cell debris (e.g., apoptotic and necrotic cells) promote tumor
              growth and metastasis - possibly through generation of
              proinflammatory eicosanoids and suppression of cancer-immunity
              cycle. Immunotherapies are emerging as novel treatment options for
              many malignancies but poor response rate and adverse events
              associated with overactivation of the immune system leads to
              discontinuation of therapy, hospital admission, or management with
              systemic immunosuppressive drugs.
            </p>

            <b>
              <em>
                There is high need for novel therapies that can improve the
                response rate and regulate the immune response.
              </em>
            </b>
          </div>
        </div>
      </div>
      <div class="science-container">
        <h4 class="science-title">Painful Peripheral Neurotheraphy</h4>
        <button
          class="btn learn-btn"
          type="button"
          data-toggle="collapse"
          data-target="#learn-more-three"
          aria-expanded="false"
          aria-controls="collapseExample"
        >
          Learn More
        </button>
        <div class="collapse" id="learn-more-three">
          <div class="card card-body">
            <p>
              Peripheral neuropathy is a serious nerve damage complication that
              affects over 16 million Americans and is causally linked to a
              number of diseases including diabetes, cancer, shingles,
              infections such as HIV, chronic back pain, stroke, and multiple
              sclerosis. The most commonly prescribed drug classes for
              neuropathic pain such as antidepressants, serotonin-norepinephrine
              reuptake inhibitors, anticonvulsants and opioids, have limited
              efficacy and dose-limiting adverse effects. No single agent
              provides optimal balance of safety, tolerability, and efficacy. As
              a result, treatment of peripheral neuropathy continues to be
              characterized by a high rate of polypharmacy and switching from
              one agent to another.
            </p>
            <p>
              All currently approved treatments for painful peripheral
              neuropathy provide only symptomatic relief.
            </p>

            <div class="science-image no-top-margin">
              <img src="images/ppn.png" />
            </div>

            <p>
              <b>
                <em>
                  There are no FDA-approved therapies for prevention or reversal
                  of peripheral neuropathy.
                </em>
              </b>
            </p>
            <p>
              <b>
                <em>
                  There is urgent need for non-opioid, safe and effective
                  therapies for neuropathic and chronic pain.
                </em>
              </b>
            </p>
          </div>
        </div>
      </div>
    </div>

    <footer>
      <h5 class="footer-title">NeuroPn</h5>
      <div class="footer-content">
        <p class="footer-address">
          <span>4989 Peachtree Parkway</span>
          <span>Suite 200</span>
          <span>Peachtree Corners</span>
          <span>GA 30092 USA</span>
        </p>
        <p class="footer-contact">
          <span>404-939-5786</span>
          <span>business@neuropn.com</span>
        </p>
      </div>
    </footer>

    <!-- Optional JavaScript -->
    <!-- jQuery first, then Popper.js, then Bootstrap JS -->
    <script
      src="https://code.jquery.com/jquery-3.5.1.slim.min.js"
      integrity="sha384-DfXdz2htPH0lsSSs5nCTpuj/zy4C+OGpamoFVy38MVBnE+IbbVYUew+OrCXaRkfj"
      crossorigin="anonymous"
    ></script>
    <script
      src="https://cdn.jsdelivr.net/npm/popper.js@1.16.1/dist/umd/popper.min.js"
      integrity="sha384-9/reFTGAW83EW2RDu2S0VKaIzap3H66lZH81PoYlFhbGU+6BZp6G7niu735Sk7lN"
      crossorigin="anonymous"
    ></script>
    <script
      src="https://stackpath.bootstrapcdn.com/bootstrap/4.5.2/js/bootstrap.min.js"
      integrity="sha384-B4gt1jrGC7Jh4AgTPSdUtOBvfO8shuf57BaghqFfPlYxofvL8/KUEfYiJOMMV+rV"
      crossorigin="anonymous"
    ></script>
  </body>
</html>
